{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:54:09Z","timestamp":1781610849987,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Financial toxicity (FT), first reported in oncologic patients and generally defined as harm to patients caused by the cost of treatment, is less well described in non-malignant urology. In chronic conditions related to lower urinary tract symptoms (LUTS), such as BPH, treatment costs may result in a significant substantial burden. The goal of this study was to characterize the association between FT and LUTS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional web-based survey was administered to a random sample of adult men through a national registry of volunteers (ResearchMatch). Disease-specific information, validated symptom scores, and an 11-item measure of LUTS-related financial toxicity were used to characterize participants. Multivariable logistic regression was performed to identify predictors of financial toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 294 respondents with a self-reported history of BPH-associated LUTS were included, 41% of whom met the criteria for financial toxicity. Men with FT had worse LUTS symptom scores across all measures (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The presence of stress, urge, or mixed incontinence was significantly higher in men with FT (52% vs. 8%, 46% vs. 15%, and 36% vs. 5% respectively;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Men with FT spent more out-of-pocket on incontinence products than those without FT (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). On multivariable analysis, mixed incontinence was a predictor of FT (OR 3.233, 95% CI 1.15\u20139.084).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Two of five men with LUTS met the criteria for financial toxicity. These men had worse urinary symptom scores, higher rates of all types of incontinence, and higher out-of-pocket costs for incontinence products.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-025-01895-4","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T11:18:00Z","timestamp":1755775080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Financial toxicity in lower urinary tract symptoms amongst men"],"prefix":"10.1186","volume":"25","author":[{"given":"Wilson","family":"Sui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Camila Velasquez","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feres Camargo","family":"Maluf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan Al","family":"Azzawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavanya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"1895_CR1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/s0022-5347(17)49698-4","volume":"132","author":"SJ Berry","year":"1984","unstructured":"Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474\u20139. https:\/\/doi.org\/10.1016\/s0022-5347(17)49698-4.","journal-title":"J Urol"},{"key":"1895_CR2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s11884-010-0067-2","volume":"5","author":"JK Parsons","year":"2010","unstructured":"Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rep. 2010;5:212\u20138. https:\/\/doi.org\/10.1007\/s11884-010-0067-2.","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"1895_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0090-4295(01)01506-0","volume":"59","author":"G Welch","year":"2002","unstructured":"Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the health professionals Follow-up study. Urology. 2002;59:245\u201350. https:\/\/doi.org\/10.1016\/S0090-4295(01)01506-0.","journal-title":"Urology"},{"key":"1895_CR4","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306\u201314. https:\/\/doi.org\/10.1016\/j.eururo.2006.09.019. discussion 1314\u20131315.","journal-title":"Eur Urol"},{"key":"1895_CR5","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.urology.2008.03.057","volume":"72","author":"JK Parsons","year":"2008","unstructured":"Parsons JK, Bergstrom J, Silberstein J, Barrett-Connor E. Prevalence and characteristics of lower urinary tract symptoms in men aged\u2009>\u2009or =\u200980 years. Urology. 2008;72:318\u201321. https:\/\/doi.org\/10.1016\/j.urology.2008.03.057.","journal-title":"Urology"},{"key":"1895_CR6","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1097\/01.ju.0000152318.79184.6f","volume":"173","author":"CS Saigal","year":"2005","unstructured":"Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol. 2005;173:1309\u201313. https:\/\/doi.org\/10.1097\/01.ju.0000152318.79184.6f.","journal-title":"J Urol"},{"key":"1895_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1377\/hlthaff.2014.1107","volume":"34","author":"M Hartman","year":"2015","unstructured":"Hartman M, Martin AB, Lassman D, Catlin A, National Health Expenditure Accounts Team. National health spending in 2013: growth slows, remains in step with the overall economy. Health Aff (Millwood). 2015;34:150\u201360. https:\/\/doi.org\/10.1377\/hlthaff.2014.1107.","journal-title":"Health Aff (Millwood)"},{"key":"1895_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/JU.0000000000000499","volume":"203","author":"C Welliver","year":"2020","unstructured":"Welliver C, Feinstein L, Ward JB, Fwu C-W, Kirkali Z, Bavendam T, et al. Trends in lower urinary tract symptoms associated with benign prostatic hyperplasia, 2004 to 2013: the urologic diseases in America project. J Urol. 2020;203:171\u20138. https:\/\/doi.org\/10.1097\/JU.0000000000000499.","journal-title":"J Urol"},{"key":"1895_CR9","unstructured":"Urologic Diseases in America. 2024 UDA Data Report: Epidemiology of non-malignant urologic disease in the United States. n.d."},{"key":"1895_CR10","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/nau.24348","volume":"39","author":"AL Burnett","year":"2020","unstructured":"Burnett AL, Walker DR, Feng Q, Johnston KM, Lozano-Ortega G, Nimke D, et al. Undertreatment of overactive bladder among men with lower urinary tract symptoms in the united states: A retrospective observational study. Neurourol Urodyn. 2020;39:1378\u201386. https:\/\/doi.org\/10.1002\/nau.24348.","journal-title":"Neurourol Urodyn"},{"key":"1895_CR11","doi-asserted-by":"publisher","unstructured":"Knight TG, Deal AM, Dusetzina SB, Muss HB, Choi SK, Bensen JT, et al. Financial toxicity in adults with cancer: adverse outcomes and noncompliance. J Oncol Pract. 2018;JOP1800120. https:\/\/doi.org\/10.1200\/JOP.18.00120.","DOI":"10.1200\/JOP.18.00120"},{"key":"1895_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40271-016-0204-x","volume":"10","author":"LG Gordon","year":"2017","unstructured":"Gordon LG, Merollini KMD, Lowe A, Chan RJ. A systematic review of financial toxicity among Cancer survivors: we can\u2019t pay the Co-Pay. Patient. 2017;10:295\u2013309. https:\/\/doi.org\/10.1007\/s40271-016-0204-x.","journal-title":"Patient"},{"key":"1895_CR13","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.juro.2017.10.049","volume":"199","author":"MM Casilla-Lennon","year":"2018","unstructured":"Casilla-Lennon MM, Choi SK, Deal AM, Bensen JT, Narang G, Filippou P, et al. Financial toxicity among patients with bladder cancer: reasons for delay in care and effect on quality of life. J Urol. 2018;199:1166\u201373. https:\/\/doi.org\/10.1016\/j.juro.2017.10.049.","journal-title":"J Urol"},{"key":"1895_CR14","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","volume":"34","author":"SD Ramsey","year":"2016","unstructured":"Ramsey SD, Bansal A, Fedorenko CR, Blough DK, Overstreet KA, Shankaran V, et al. Financial insolvency as a risk factor for early mortality among patients with Cancer. J Clin Oncol. 2016;34:980\u20136. https:\/\/doi.org\/10.1200\/JCO.2015.64.6620.","journal-title":"J Clin Oncol"},{"key":"1895_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.29808","volume":"122","author":"HP Kale","year":"2016","unstructured":"Kale HP, Carroll NV. Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer. 2016;122:283\u20139. https:\/\/doi.org\/10.1002\/cncr.29808.","journal-title":"Cancer"},{"key":"1895_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.urology.2023.04.040","volume":"179","author":"V Glazyrine","year":"2023","unstructured":"Glazyrine V, Au D, Starkey J, Thompson J, Parker W. Evaluating financial toxicity in urologic practice. Urology. 2023;179:16\u201322. https:\/\/doi.org\/10.1016\/j.urology.2023.04.040.","journal-title":"Urology"},{"key":"1895_CR17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cncr.30369","volume":"123","author":"JA de Souza","year":"2017","unstructured":"de Souza JA, Yap BJ, Wroblewski K, Blinder V, Ara\u00fajo FS, Hlubocky FJ, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the comprehensive score for financial toxicity (COST). Cancer. 2017;123:476\u201384. https:\/\/doi.org\/10.1002\/cncr.30369.","journal-title":"Cancer"},{"key":"1895_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42:377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"J Biomed Inf"},{"key":"1895_CR19","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/s0022-5347(17)36966-5","volume":"148","author":"MJ Barry","year":"1992","unstructured":"Barry MJ, Fowler FJ, O\u2019Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American urological association symptom index for benign prostatic hyperplasia. The measurement committee of the American urological association. J Urol. 1992;148:1549\u201357. https:\/\/doi.org\/10.1016\/s0022-5347(17)36966-5. discussion 1564.","journal-title":"J Urol"},{"key":"1895_CR20","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/nau.20041","volume":"23","author":"K Avery","year":"2004","unstructured":"Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004;23:322\u201330. https:\/\/doi.org\/10.1002\/nau.20041.","journal-title":"Neurourol Urodyn"},{"key":"1895_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/nau.20674","volume":"28","author":"A Klovning","year":"2009","unstructured":"Klovning A, Avery K, Sandvik H, Hunskaar S. Comparison of two questionnaires for assessing the severity of urinary incontinence: the ICIQ-UI SF versus the incontinence severity index. Neurourol Urodyn. 2009;28:411\u20135. https:\/\/doi.org\/10.1002\/nau.20674.","journal-title":"Neurourol Urodyn"},{"key":"1895_CR22","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/nau.25007","volume":"41","author":"LP Chisholm","year":"2022","unstructured":"Chisholm LP, Sebesta EM, Gleicher S, Kaufman M, Dmochowski RR, Reynolds WS. The burdens of incontinence: quantifying incontinence product usage and costs in women. Neurourol Urodyn. 2022;41:1601\u201311. https:\/\/doi.org\/10.1002\/nau.25007.","journal-title":"Neurourol Urodyn"},{"key":"1895_CR23","unstructured":"Validation of a financial. toxicity (FT) grading system. J Clin Oncol. n.d. https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2017.35.15_suppl.6615. Accessed 10 Sept 2024."},{"key":"1895_CR24","doi-asserted-by":"publisher","first-page":"117863292110573","DOI":"10.1177\/11786329211057352","volume":"14","author":"G Pavela","year":"2021","unstructured":"Pavela G, Fifolt M, Tison SE, Allison M, Burton BS, Ford EW. Re-Validation of the comprehensive score for financial toxicity (COST): assessing the scale\u2019s utility in chronic disease populations. Health Serv Insights. 2021;14:11786329211057352. https:\/\/doi.org\/10.1177\/11786329211057352.","journal-title":"Health Serv Insights"},{"key":"1895_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.urology.2023.01.010","volume":"174","author":"SA Setia","year":"2023","unstructured":"Setia SA, Gelikman DG, Cabo J, Hsi RS. Patient-Reported financial toxicity associated with management of nephrolithiasis. Urology. 2023;174:52\u20137. https:\/\/doi.org\/10.1016\/j.urology.2023.01.010.","journal-title":"Urology"},{"key":"1895_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.urology.2022.08.053","volume":"171","author":"J Cabo","year":"2023","unstructured":"Cabo J, Gelikman DG, Hsi RS. The financial burden of nephrolithiasis and predictors of Disease-specific financial toxicity. Urology. 2023;171:57\u201363. https:\/\/doi.org\/10.1016\/j.urology.2022.08.053.","journal-title":"Urology"},{"key":"1895_CR27","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bju.15286","volume":"127","author":"BM Launer","year":"2021","unstructured":"Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia. BJU Int. 2021;127:722\u20138. https:\/\/doi.org\/10.1111\/bju.15286.","journal-title":"BJU Int"},{"key":"1895_CR28","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/JOM.0000000000000839","volume":"58","author":"AM Meraya","year":"2016","unstructured":"Meraya AM, Sambamoorthi U. Chronic condition combinations and productivity loss among employed nonelderly adults (18 to 64 Years). J Occup Environ Med. 2016;58:974\u20138. https:\/\/doi.org\/10.1097\/JOM.0000000000000839.","journal-title":"J Occup Environ Med"},{"key":"1895_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.mcna.2010.08.013","volume":"95","author":"CG Roehrborn","year":"2011","unstructured":"Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 2011;95:87\u2013100. https:\/\/doi.org\/10.1016\/j.mcna.2010.08.013.","journal-title":"Med Clin North Am"},{"key":"1895_CR30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/fampra\/cmh622","volume":"21","author":"S Horrocks","year":"2004","unstructured":"Horrocks S, Somerset M, Stoddart H, Peters TJ. What prevents older people from seeking treatment for urinary incontinence? A qualitative exploration of barriers to the use of community continence services. Fam Pract. 2004;21:689\u201396. https:\/\/doi.org\/10.1093\/fampra\/cmh622.","journal-title":"Fam Pract"},{"key":"1895_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003698","volume":"211","author":"JS Sandhu","year":"2024","unstructured":"Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol. 2024;211:11\u20139. https:\/\/doi.org\/10.1097\/JU.0000000000003698.","journal-title":"J Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01895-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01895-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01895-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:20:05Z","timestamp":1781608805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-025-01895-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1895"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01895-4","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was IRB-approved (IRB #23-38991) approved by the Bioethics Committee of the University of California (UCSF) Medical School.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants were informed that completing the survey implied consent to participate in the study. No personally identifiable information was collected, and responses were anonymized to protect participants\u2019 privacy. Given the anonymous nature of the survey and the minimal risk involved, formal written consent was not required, in accordance with institutional and ethical guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}